English, PDF, 2,527kb
A collapse in international investment flows in Europe may be a canary in the coal mine for the region's economy: Guest commentary by Michael Gestrin of the OECD in the US and European editions of Bloomberg Brief on 11 November 2014.
English, PDF, 1,045kb
Global FDI flows collapsed with the global financial crisis in 2008 and remain 40% below pre-crisis levels. A major reason for this is the EU. While FDI flows in the rest of the world recovered by 2010, the EU continues to struggle due to structural factors that are undermining the quality of the EU’s investment environment. The paper analyses why and puts forward policy options. It is part of the Investment Insights series.
English, PDF, 669kb
This is a consolidated report covering investment measures taken between 16 February and 15 September 2014. The present report was prepared for the Freedom of Investment Roundtable 21 held on 14 October 2014.
Each year, the Competition Committee holds several Best Practice Roundtables. This list contains links to the proceedings from these roundtables from 1995 to the present date.
Pharmaceuticals are special products due to special characteristics in supply and demand. Their distribution is heavily regulated to ensure that drugs are accessible, affordable, and safely consumed. Competition can and should play a role in ensuring that the pharmaceuticals distribution market works well for consumers. The 2014 Global Forum on Competition addressed competition issues in the distribution of pharmaceuticals.
English, PDF, 1,050kb
This report by OECD and UNCTAD compiles G20 investment measures taken between 2 April 2009 and 15 October 2014.
Nationally and internationally competitive markets should be promoted in order to provide consumers with greater choice amongst financial services. The OECD Competition Committee discussed the Role of Competition in Financial Consumer Protection in February 2014.